suggesting a diminished impact of MM on health-related quality of life (HRQoL) post cilta-cel
treatment. The most common expectations of cilta-cel at pretreatment were remission (40.7%),
extended life expectancy (14.8%), less treatment (11.1%), and cure (11.1%). Changes considered
meaningful with cilta-cel treatment were improved MM symptoms (70.4%), return to perceived
normalcy (40.7%), and ability to be more physically active (33.3%). At Day 100 and 184, respectively,
78.3% and 91.7% of patients reported that their expectations of cilta-cel were met/exceeded (Figure
A), and 52.2% and 70.8% perceived their cilta-cel treatment experience as exclusively better than
previous treatment experiences (Figure B).
Patients treated with cilta-cel experienced reductions in both symptoms associated with RRMM and
impact of MM on HRQoL. Pretreatment expectations of cilta-cel were met or exceeded, and most
patients reported their experience was better than with prior MM treatments.
